Literature DB >> 22200130

The use of ECT and MST in treating depression.

Charlotte L Allan1, Klaus P Ebmeier.   

Abstract

Electroconvulsive therapy (ECT) has been used clinically since 1938. Its most common use is in the treatment of depression: first line treatment where rapid recovery is a priority, but more frequently as an effective treatment for patients who do not respond to pharmacological and psychological approaches. Whilst it is widely hailed as an effective treatment, concerns about its effect on cognition remain. The development of magnetic seizure therapy (MST) over the past decade has attempted to devise a therapy with comparable efficacy to ECT, but without the associated cognitive side effects. The rationale for this is that MST uses magnetic fields to induce seizures in the cortex, without electrical stimulation of brain structures involved with memory. MST has been used successfully in the treatment of depression, yet there is a dearth of literature in comparison with ECT. We present a systematic review of the literature on ECT (from 2009-2011) and MST (from 2001-2011).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22200130     DOI: 10.3109/09540261.2011.614223

Source DB:  PubMed          Journal:  Int Rev Psychiatry        ISSN: 0954-0261


  4 in total

1.  Magnetic seizure therapy.

Authors:  Rishabh Singh; Rachit Sharma; Jyoti Prakash; Kaushik Chatterjee
Journal:  Ind Psychiatry J       Date:  2021-10-22

2.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

3.  Efficacy of electroconvulsive therapy for comorbid frontotemporal dementia with bipolar disorder.

Authors:  Sean Paul; Jennifer Goetz; Jeffrey Bennett; Tessy Korah
Journal:  Case Rep Psychiatry       Date:  2013-05-12

Review 4.  Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use.

Authors:  Helge H O Müller; Sebastian Moeller; Caroline Lücke; Alexandra P Lam; Niclas Braun; Alexandra Philipsen
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.